Table A10.
Treatment intensity and occurrence of TRAE.
| No TRAE | TRAE | Total | p-Value | |||||
|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |||
| Overall | Dt * | 31 | 24.6 | 55 | 47.8 | 86 | 35.7 | <0.001 |
| q14 | 14 | 11.1 | 18 | 15.7 | 32 | 13.3 | ||
| q21 | 27 | 21.4 | 22 | 19.1 | 49 | 20.3 | ||
| q28 | 42 | 33.3 | 17 | 14.8 | 59 | 24.5 | ||
| q42 | 12 | 9.5 | 3 | 2.6 | 15 | 6.2 | ||
| Anti-PD1 group | q14 | 14 | 16.1 | 18 | 32.1 | 32 | 22.4 | 0.023 |
| q21 | 27 | 31 | 22 | 39.3 | 49 | 34.3 | ||
| q28 | 34 | 39.1 | 13 | 23.2 | 47 | 32.9 | ||
| q42 | 12 | 13.8 | 3 | 5.4 | 15 | 10.5 | ||
| BRAF/MEK inhibitor group | dt | 31 | 79.5 | 55 | 93.2 | 86 | 87.8 | 0.086 |
| q28 | 8 | 20.5 | 4 | 6.8 | 12 | 12.2 |
* Table summarizes the initial planned intensity.